Inventiva to Showcase Lanifibranor Data at Paris MASH 2026

Inventiva, a biopharmaceutical company, will present five abstracts at the Paris MASH 2026 conference. The abstracts cover Phase 1 and Phase 2 clinical data, demonstrating lanifibranor's potential to enhance metabolic and cardiovascular outcomes in MASH patients. The studies show that lanifibranor improves insulin sensitivity, glycemic control, and lipid parameters in both diabetic and non-diabetic individuals.

Preclinical data highlight lanifibranor’s balanced pharmacology within the PPAR class, indicating potential benefits over traditional TZDs. This compound is currently under evaluation in the Phase 3 NATiV3 trial, with results anticipated later this year.